Navigation Links
Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
Date:5/23/2011

RICHMOND, Calif., May 23, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).  The meeting was held in Seattle from May 18-21, 2011.

"Sangamo's ZFP technology is revolutionizing cell and gene therapies," stated Barrie Carter, Ph.D., a member of Sangamo's scientific advisory board and President of ASGCT for 2010-2011. "ZFP Nuclease (ZFN) technology provides an efficient and precise process for editing any DNA sequence in a cell, making development of therapeutic gene-editing applications a reality.  Sangamo has ongoing human clinical trials to evaluate ZFN-based therapeutics in HIV/AIDS and ZFP transcription factors (ZFP TFs) in neuroregeneration. As this technology functions at the DNA level, it can be applied to numerous diseases and any disease-related gene."

ASGCT meeting presentations included previously described preliminary clinical data from Sangamo's ongoing Phase 1 clinical trial in HIV/AIDS (SB-728-902) as well as data from preclinical and research-stage human therapeutic programs.  Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and monogenic diseases such as hemophilia, ADA-SCID, retinal neurodegeneration and epidermolysis bullosa.  Positive preclinical data were also presented from studies of Sangamo's ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of stroke.

"These data presentations illustrate the broad range of potential applications for ZFP Therapeutics including monogenic diseases,
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
2. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
3. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
4. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
5. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
11. Sangamo Announces Closing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 The ... North America , Europe ... world (RoW). The global departmental PACS market is expected to ... between 2014 and 2019. Browse through the TOC ... the industry trends and segments, with help of various tables ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 ... company, and the Clinic for Special Children today announced ... will be utilized for the diagnosis of rare genetic ... Strasburg, Pennsylvania , the Clinic for Special Children ... population with a relatively high incidence of genetic disease. ...
(Date:5/28/2015)... -- According to Kalorama Information, CVS Health Corporation,s agreement of ... fits a prevailing trend in the healthcare industry – ... U.S. long term care industry has experienced steady growth ... population increases demand for all forms of long term ... The Long Term Care Market: Nursing Homes, Home ...
Breaking Medicine Technology:Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 2Departmental PACS Market is Expected to Reach $3,807.4 Billion by 2019, at a CAGR of 10.0% From 2014 to 2019 3Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 2Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 3Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 2Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 3Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 4
... , , , ... reported this week that the prevalence of obesity among Americans is now ... and heart disease, often in the same patient, and is referred to ... underpinnings of metabolic syndrome. , , The ...
... , , ROCKVILLE, Maryland ... HGSI ) and GlaxoSmithKline PLC (GSK) today announced ... BLISS-52, the first of two pivotal Phase 3 trials in ... the placebo-controlled BLISS-52 study, the results showed that belimumab plus ...
Cached Medicine Technology:Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 4Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 5Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 6Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 7Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 8Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 9Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 10
(Date:5/28/2015)... Orem, UT—Dymicron, Inc., (dymicron.com) confirmed the successful completion of ... total disc replacement device. The two surgeries were performed ... American Institute of Minimally Invasive Surgery (AIMIS) in Cyprus. ... implantation of the Dymicron devices,” said Dr. William D. ... Neurosurgery for the University Medical Center, Las Vegas, Nevada. ...
(Date:5/28/2015)... 28, 2015 Career Step, an online ... to announce that Career Step Executive Vice President Mike ... 4 webinar presented by ICD10monitor in conjunction with Kimberly ... Mr. Hodgson and Ms. Carr will be discussing the ... ICD-10 transition. , “We have worked closely with HRS ...
(Date:5/28/2015)... 28, 2015 Aureus Medical Group (web: ... practitioner jobs, has announced that it will participate as ... 2015 National Conference to be held June 9-14, 2015 ... educational programming, networking opportunities, and exhibits with products and ... Practice division will be available to speak with ...
(Date:5/28/2015)... Atlanta-based Thrive Senior Living has announced ... summer on an innovative new Assisted Living community in ... connectivity in a unique, resort-like environment, Thrive at Jones ... southern hospitality to create a distinctive experience for a ... will feature luxuriously appointed resident apartments, a spa, beauty ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2
... ATLANTA , Jan. 13 More than a ... over 40 years old. Yet there have been very few campaigns ... tank devoted exclusively to combating AIDS among African Americans, is about ... to help Black people ages 40 and up become more aware ...
... LOS ANGELES , Jan. 13 Buying mail-order ... new research suggests. , In a first-of-its-kind study, researchers from ... Calif. found that patients with diabetes, high blood pressure or ... to take them as prescribed by their doctors than did patients ...
... sleep disorders , WEDNESDAY, Jan. 13 (HealthDay News) ... whose husbands were deployed have higher rates of depression, ... the wives of soldiers who stayed home, a new ... of more than 250,000 wives, accounting for most women ...
... both humans and chimpanzees , WEDNESDAY, Jan. 13 (HealthDay News) ... faster than expected in humans and chimpanzees over the past ... a common ancestor, researchers report. , The new study challenges ... slowly decaying or stagnating. , The Y chromosome is present ...
... , , LAS VEGAS , Jan. 13 ... and Chief Medical Officer of Cenegenics® Medical Institute of ... P. Mintz Award for Clinical Excellence in Age Management ... Institute.     , (Photo: http://www.newscom.com/cgi-bin/prnh/20100113/FL36991 ) , ...
... , The 1-888-606-1688 "helpline" will connect callers with ... NEW YORK , Jan. 13 Helping ... recommendations, the American Parkinson Disease Association (APDA) and Boston ... for Rehabilitation. The center,s toll-free "helpline" telephone number is 1-888-606-1688, ...
Cached Medicine News:Health News:AIDS Campaign Targets Neglected Segment of Black America 2Health News:AIDS Campaign Targets Neglected Segment of Black America 3Health News:AIDS Campaign Targets Neglected Segment of Black America 4Health News:Mail-Order Pharmacy Use Could Improve Patients' Medication Adherence 2Health News:Mail-Order Pharmacy Use Could Improve Patients' Medication Adherence 3Health News:Mail-Order Pharmacy Use Could Improve Patients' Medication Adherence 4Health News:Mail-Order Pharmacy Use Could Improve Patients' Medication Adherence 5Health News:Deployment Takes Toll on Army Wives 2Health News:Deployment Takes Toll on Army Wives 3Health News:Males' Y Chromosome Not in Decline 2Health News:Dr. Robert D. Willix Jr. M.D., CEO and CMO of Cenegenics(R) Medical Institute of Boca Raton Appointed Chief Medical Officer of Cenegenics(R) Medical Institute, World's Largest Preventive Age Management Practice 2Health News:Dr. Robert D. Willix Jr. M.D., CEO and CMO of Cenegenics(R) Medical Institute of Boca Raton Appointed Chief Medical Officer of Cenegenics(R) Medical Institute, World's Largest Preventive Age Management Practice 3Health News:APDA Launches First-of-its-Kind Parkinson's Rehab Resource Center 2Health News:APDA Launches First-of-its-Kind Parkinson's Rehab Resource Center 3
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
... assays are designed for ... 2000, a high-throughput, continuous ... IMMULITE 2000 offers testing ... a rapidly expanding menu ...
... Diagnostic Automation, Inc. (DAI) ENA Enzyme-Linked Immunosorbent Assay ... to Sm, RNP, Ro, La, Scl-70, and Jo-1 ... to be used to detect antibodies in a ... assay are to be used as an aid ...
Medicine Products: